A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma is a PHASE1 clinical asset sponsored by Peking Union Medical College Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: CD19-directed CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: B-cell Non-Hodgkin Lymphoma
Modality: cell therapy
Target: CD19-directed CAR-T cells
Sponsor: Peking Union Medical College Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19-directed CAR-T cells
View original source fields
Condition raw: B-cell Non-Hodgkin Lymphoma
Condition normalized: B-cell Non-Hodgkin Lymphoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD19-directed CAR-T cells
Target normalized: CD19-directed CAR-T cells